长护险有望催生万亿级护理需求，重视创新器械

Investment Rating - The report maintains an "Outperform" rating for the industry [7]. Core Insights - The long-term care insurance (LTCI) is expected to generate a trillion-level demand for nursing services, emphasizing the importance of innovative medical devices [2][4]. - The report highlights a significant increase in the number of disabled individuals in China, projected to reach 62 million by 2050, leading to a related care demand of approximately 1.7 trillion yuan [4][16]. - The LTCI system is in an accelerated establishment phase, with the government increasingly focusing on its implementation since 2021 [4][18]. Summary by Sections Long-term Care Insurance - The LTCI is anticipated to become a core payment mechanism for nursing services, with a projected care demand of 1.7 trillion yuan by 2050 due to the rising number of disabled individuals [4][16]. - The number of individuals covered by LTCI has grown from 108 million in 2020 to 183 million in 2023, with a significant increase in both income and expenditure of the LTCI fund [27][28]. - The report outlines various methods to estimate the potential income scale of LTCI, suggesting it could reach between 1,773 billion and 20,130 billion yuan based on different assumptions [41][46]. Market Review and Trends - The report notes a 4.2% decline in the CITIC Pharmaceutical Index for the week of June 16-20, 2025, underperforming the CSI 300 Index by 3.8 percentage points [3][49]. - The report identifies key stocks that performed well during the week, including Anglikang (+21.2%) and Yuekang Pharmaceutical (+19.3%) [3][64]. - The overall market sentiment in the pharmaceutical sector is currently weak, with a 25.6% decrease in trading volume compared to the previous week [5][63]. Investment Recommendations - The report suggests focusing on innovative medical devices and pharmaceuticals as key investment themes, particularly those with strong performance trends and potential for growth [5][6]. - Specific companies to watch include Huada Zhizao, Huitai Medical, and Xinda Biopharma, among others [6][12].